The effect of orlistat in the treatment of non-alcoholic fatty liver in adolescents with overweight and obese

Conclusion: The findings of our study reported that orlistat improved NAFLD-related factors and metabolic syndrome-related factors compared to placebo for 12 weeks.Trial Registration: (Clinical trial registry number: IRCT20220409054467N2, with a registration date of 2022 –05-13).What is Known:• Among the interventions of interest for the management of pediatric NAFLD, we can mention lifestyle and pharmaceutical measures.What is New:• This study was conducted to determine whether adolescents with NAFLD would improve with treatment intervention with orlistat.• The findings of our study reported that orlistat improved NAFLD-related factors and metabolic syndrome-related factors compared to placebo for 12 weeks.
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research